

M&A Lab

November 13, 2008

RANBAXY-DAIICHI DEAL DISSECTED

Dear All,

With the completion of acquisition of 63.92% equity stake in Ranbaxy Laboratories Limited ("**Ranbaxy**"), India's largest pharmaceutical company, by Japanese pharma major Daiichi Sankyo Co., Ltd. ("**Daiichi**"), on November 7, 2008, it would be interesting to analyze the key legal and tax issues that arose from the beginning till the completion of this landmark deal.

For a detailed analysis of the legal and tax issues, [please click here for the document](#).

As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative.

– Ruchi Biyani, Vaidhyanadhan Iyer & Nishchal Joshipura

You can direct your queries or comments to Team M&A

DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Research Papers

Evolution of Generative AI

July 11, 2024

From Capital to Impact: Role of Blended Finance

June 15, 2024

Opportunities in GIFT City

June 14, 2024

Research Articles

Private Client Insights - Sustainable Success: How Family Constitutions can Shape Corporate Governance, Business Succession and Familial Legacy

January 25, 2024

Private Equity and M&A in India: What to Expect in 2024?

January 23, 2024

Emerging Legal Issues with use of Generative AI

October 27, 2023

Audio

Dabba Trading and Its Regulatory Landscape in India

July 25, 2024

Pursuing Remedies against Non-signatories in Investment Agreements

July 03, 2024

Why is the ad industry unhappy with MIB's self-declaration mandate?

June 18, 2024

NDA Connect

Connect with us at events, conferences and seminars.

NDA Hotline

[Click here to view Hotline archives.](#)

Video

Union Budget: Key takeaways for Private Equity Investors and Foreign Companies

July 24, 2024

**Self Declaration Certificate For Ads:
Decoding The Complexities Of Ad
Regulations**

July 08, 2024

**Future of India-Mauritius tax treaty –
Impact of new Protocol on M&A
deals and Private Equity structures**

April 23, 2024
